Express . . . Seek accelerated approval, innovative antibody conjugal drug treatment for cervical cancer Phase 2 clinical results are positive.

▎ Seattle genetics, editor of the content team of Wuxi apptec, recently announced that tisotumab vedotin, an innovative antibody coupled drug (ADC) jointly developed by the company and genmab company, has achieved positive top-line results in a potentially registered phase 2 clinical trial called innovatv204.in the treatment of patients with recurrent or metastatic cervical cancer, the objective response rate (ORR) confirmed by independent center review was 24% [95% CI: 15.9% - 33.3%], and the median duration of remission (DOR) was 8.3 months.detailed data will be presented to the upcoming medical conference.at the same time, the company will discuss with FDA to explore the possibility of obtaining accelerated approval based on this data.cervical cancer originates from the cells in the inner wall of the cervix., although routine physical examination and human papillomavirus (HPV) vaccine have reduced the incidence rate of cervical cancer, it is still one of the main causes of cancer deaths worldwide, and more than 310 thousand women die every year.tisotumab vedotin is a kind of research ADC which targets tissue factor (TF) jointly developed by Seattle genetics and genmab.it combines anti TF antibodies from genmab and antibody coupling technology from Seattle genetics.tissue factor is highly expressed in cervical cancer, which can promote tumor growth, angiogenesis and cancer metastasis.at present, the orr of standard treatment for recurrent and / or metastatic cervical cancer is limited, usually less than 15%, and the median overall survival time ranges from 6.0 to 9.4 months.at present, the ADC is also in another clinical trial in combination with chemotherapy, keytruda, or Avastin to treat patients with cervical cancer.in addition to the treatment of cervical cancer, tisotumab vedotin is also being evaluated in other tumor types that express tissue factors, including ovarian cancer and other solid tumors."patients with recurrent or metastatic cervical cancer have very limited treatment options when their disease progresses after first-line chemotherapy, and their demand for new treatment options is obviously not met," said Dr. Roger Dansey, chief medical officer, Seattle genetics. "Tisotumab vedotin has demonstrated clinically significant and sustained objective remission.we look forward to discussing with the FDA the possibility of submitting a biological product license application to support accelerated approval."reference: [1] Seattle genetics announcements positive topline results from phase 2 clinical trial of tisotumab vedotin in recurrent or metastatic medical cancer. Retrieved June 29, 2020, from note: This paper aims to introduce the progress of medical health research, not the recommendation of treatment options.if you need guidance on treatment plan, please go to a regular hospital.